Market News & Trends
Evogene Announces Collaboration With Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design
Evogene Ltd. recently announced a collaboration with Google Cloud to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene’s ChemPass…
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies for Ulcerative Colitis Treatment
Palisade Bio, Inc. recently announced the presentation of data from two translational studies demonstrating the ex vivo bioactivation of PALI-2108 in stool samples and whole blood.…
Sterling Pharma Solutions Expands GMP ADC Manufacturing Capacity at Deeside, UK
Sterling Pharma Solutions recently announced the second phase of an expansion strategy at its Deeside, UK, site to support antibody-drug conjugate (ADC) development, with a…
Abzena Announces Major Expansion in Microbiology Laboratory Space in Support of Biologic Manufacturing
Abzena recently announced a significant expansion in their quality control (QC) testing capabilities at their San Diego, CA, biologics development and cGMP manufacturing site. The…
PCI Pharma Services Wins Supply Chain Excellence Award for Groundbreaking Digital Platform to Manage Clinical Trials & Commercial Lifespans
PCI Pharma Services has earned a Supply Chain Excellence Award USA for a first-of-its-kind digital solution for clinical trials and commercial lifespan management. The company’s pci…
Novartis Scemblix FDA Approved in Newly Diagnosed CML, Offering Superior Efficacy & Favorable Safety & Tolerability Profile
Novartis recently announced Scemblix (asciminib) was granted accelerated approval by the US FDA for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in…
MariMed Commences Manufacturing Operations in Missouri
MariMed Inc. recently announced the start of cannabis product manufacturing in Missouri. MariMed’s award-winning products are expected to be available across the state in time for…
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients With Solid Tumors
Numab Therapeutics AG recently announced the start of a Phase 1 clinical trial evaluating NM32, a next-generation tri-specific immuno-oncology therapeutic targeting the receptor tyrosine kinase-like…
Enlivex Receives Notice of Allowance for Patent Application Covering the Use of Allocetra in Patients With Osteoarthritis
Enlivex Therapeutics Ltd. recently announced the Japanese Patent Office issued a notice of allowance for patent application number 2022-512861 titled Therapeutic Apoptotic Cells for Treatment…
Tiziana Life Sciences Announces Positive Results From Ozempic & Nasal Anti-CD3 Combination Study
Tiziana Life Sciences, Ltd. recently announced positive results demonstrating the anti-inflammatory potential of its anti-CD3 antibody (foralumab) in combination with semaglutide, a GLP-1 agonist marketed…
IsomAb Announces Strategic Collaboration With Catalent
IsomAb Ltd, a UK-based biotechnology company developing isoform-specific, disease-modifying antibody treatments for serious and life-threatening diseases, recently announced it has entered into a strategic collaboration…
Naobios & Sumagen Successfully Optimize HIV Vaccine Candidate for Industrial Production
Naobios and Sumagen Canada Inc. recently announced the production of the HIV-1 vaccine candidate at bench scale. This key milestone puts Naobios in a position…
VALANX Biotech & Fina Biosolutions Introduce ClickCRM for Rapid Conjugate Vaccine Development
VALANX Biotech and Fina Biosolutions LLC recently announced the signing of a joint IP and licensing agreement. The companies will launch ClickCRM, a ready-to-conjugate version…
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
Sagimet Biosciences Inc. recently announced the successful completion of end-of-Phase 2 interactions with the US FDA, supporting the advancement of denifanstat into Phase 3 in…
Ardena Expands Bioanalytical Services in Europe
Ardena recently announced a substantial expansion of its Bioanalytical Services in the Netherlands. This strategic investment includes establishing a brand new bioanalytical lab at Ardena’s…
Eledon Pharmaceuticals Announces Positive Initial Data From Subjects With Type 1 Diabetes Treated With Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation
Eledon Pharmaceuticals, Inc. recently announced positive data for the first three islet transplant recipients treated with an immunosuppression regimen that includes tegoprubart, the company’s investigational…
Shuttle Pharma Doses First Patients in Phase 2 Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma
Shuttle Pharmaceuticals Holdings, Inc. recently announced the first three patients in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma…
Modifi Biosciences Acquired by Merck
Modifi Biosciences, Inc., a leader in the development of direct DNA modification enabled cancer therapeutics, recently announced it has been acquired by Merck, known as…
ImmunoPrecise Advances Anti-Aging Research With Mayo Clinic Study, Poised to Tap Into $81-Billion Market With AI Technology
ImmunoPrecise Antibodies Ltd. recently announced its significant contribution to a groundbreaking study. The research, led by top scientists at the Mayo Clinic, was initially published…
Monte Rosa Therapeutics Announces Global License Agreement With Novartis to Advance T & B Cell-Modulating VAV1-Directed Molecular Glue Degraders
Monte Rosa Therapeutics, Inc. recently announced a global exclusive development and commercialization license agreement with Novartis to advance VAV1 MGDs, including MRT-6160. MRT-6160 is currently in…
